UroGen Pharma Ltd. (URGN) Financial Statements
UroGen Pharma Ltd. (URGN) reported trailing twelve-month revenue of $188.7M (up 100.3% year on year) and net income of -$97.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$159.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
URGNUroGen Pharma Ltd.Follow URGN — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.2 | 1.1 | 0.0 | 11.8 | 48.0 | 64.4 | 82.7 | 90.4 | 109.8 | 188.7 | |
| Gross profit | 7.6 | -0.7 | 0.0 | 10.8 | 42.9 | 56.7 | 73.4 | 81.5 | 97.3 | 171.5 | |
| Research & development | — | — | 49.3 | 47.3 | 47.6 | 52.9 | 45.6 | 57.1 | 67.1 | 61.3 | |
| Operating income | -20.0 | -77.2 | -109.5 | -126.7 | -92.3 | -79.0 | -65.5 | -96.8 | -124.9 | -66.7 | |
| Pre-tax income | -20.0 | -75.5 | -105.1 | -125.1 | -109.4 | -108.0 | -98.3 | -124.0 | -153.4 | -98.1 | |
| Income tax | 0.0 | 0.1 | — | 3.4 | 1.4 | 1.8 | 3.9 | 2.8 | 0.1 | -0.5 | |
| Net income | -20.0 | -75.7 | -105.1 | -128.5 | -110.8 | -109.8 | -102.2 | -126.9 | -153.5 | -97.6 | |
| Diluted EPS ($) | -2.14 | -4.80 | -5.12 | -5.90 | -4.96 | — | — | — | — | — |
USD millions · SEC XBRL
UroGen Pharma Ltd. — questions
- What is UroGen Pharma Ltd.'s revenue?
- $188.7M over the twelve months to 2026-06-30, up 100.3% year on year, from its 10-Q and 10-K filings.
- What is UroGen Pharma Ltd.'s net income?
- -$97.6M over the twelve months to 2026-06-30.
- What is UroGen Pharma Ltd.'s free cash flow?
- -$159.1M over the twelve months to 2026-06-30.
Every figure on this page comes from UroGen Pharma Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.